HeartBar contains arginine, and due to increased demand for arginine and the new patent, HeartBar's sales and profits are likely to increase. This is a relatively minor product at this time. (Remodulin for secondary hypertension has been fully approved in the USA by the FDA and in Canada. The French are holding up approval in Europe, which seems certain.)UTHR believes that 2004 will be a profitable year.
1.Sales for arginine were about $20M in 2002 and are projected to be $100M in 2005 (USA total).
2.UTHR and a subsidiary market and sell supplements under the HeartBar trademark that are in several forms (bar, power and liquid I believe).
3.Each portion of the supplement (Heatrbar) contains 6 grams of L-arginine.
4.With a NEW PATENT it seems reasonable that this product will contribute more to the bottom line as interest and demand increases.
5.Dr Cooke and his research appear to be credible and he is well published (see recent posting)
6.UTHR will be profitable in 2004, according to the company.
7.I believe that this is a worthwhile investment in a small biotech company that has FDA approved products, medical electronics, supplements and a credible pipeline. Also there are acquisition possibilities.
8.Apparently you believe that this is a poor investment that can be shorted (correct me if I am wrong) Clearly we are talking about arginine as part of a diet supplement (Heartment) for cardivascular health. UTHR, with its wholly owned subsidiary, markets this product in the rapidly growing, alternative/supplement medicine world as studied by NIH (down the road from UTHR). This patent will help their bottom line.
Heartbar, as such, is not approved by the FDA but there is considerable evidence of its positive effects. I view this patent as very positive.
Here are some references for your review and comment
The HeartBar� brand of arginine-enriched dietary supplements was originally developed by Dr. John P. Cooke, M.D., Ph.D., Director of Vascular Medicine and Associate Professor of Medicine at Stanford University Medical School, based on years of research studying the role of arginine in promoting vascular health.
The healthy body uses arginine, a semi-essential amino acid found in food, to produce nitric oxide, which helps keep your blood vessels open, elastic and functioning properly - a breakthrough discovery so important, it won the 1998 Nobel Prize in Medicine.
Dr. Cooke was one of the first researchers to demonstrate that supplementing your diet with arginine may reduce the effects of impaired nitric oxide production. His research in vascular disease has been praised worldwide and has been published in over 150 scientific journal articles. Dr. Cooke is author of the recently published book, The Cardiovascular Cure: Your Self-Defense Against Heart Attack and Stroke (Random House, 2002).
Tell me genious, what is Dr. Cookes current relationship with UTHR. Also please tell me why the FTC went after them if not for making unsubstantiated claims. Or have you nor read the UTHR " Dear Custimer" letter?
I had read the letter. This is not an FDA approved drug with phases 1,2,and 3 for approval. There is substanial evidence that this is an important supplement and being a natural substance does not need FDA approval (like vitamin E). However, there is also a limit to what UTHR can claim without this formal procedure, and apparently they crossed the line. NIH has a large, controversial section under Dr. Strauss (I believe) studying these alternative supplements. Dr. Cooke is a credible researcher, but I do not know his current arrangement with UTHR.